Promising therapeutic targets in neuroblastoma. Read more about Promising therapeutic targets in neuroblastoma.
Regional cell proliferation in microdissected human prostate specimens after heavy water labeling in vivo: correlation with prostate epithelial cells isolated from seminal fluid. Read more about Regional cell proliferation in microdissected human prostate specimens after heavy water labeling in vivo: correlation with prostate epithelial cells isolated from seminal fluid.
Darinaparsin: solid tumor hypoxic cytotoxin and radiosensitizer. Read more about Darinaparsin: solid tumor hypoxic cytotoxin and radiosensitizer.
Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors. Read more about Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.
Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer. Read more about Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer.
SSBP2 variants are associated with survival in glioblastoma patients. Read more about SSBP2 variants are associated with survival in glioblastoma patients.
Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy. Read more about Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy.
Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial. Read more about Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial.
Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma. Read more about Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma.
Integrated analysis reveals critical genomic regions in prostate tumor microenvironment associated with clinicopathologic phenotypes. Read more about Integrated analysis reveals critical genomic regions in prostate tumor microenvironment associated with clinicopathologic phenotypes.
